Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Functional Technologies Corp FEBTF

GREY:FEBTF - Post Discussion

View:
Post by skyhi0 on Oct 19, 2011 1:26pm

Novozyme

has been marketing the acrylamide reducing agent for a while now and revenues are such that they are proposing a 1:5 stock split on Dec 1st to make shares more available to retail investors. Further... THEY PAY A DIVIDEND.

So... How are we doing ???

l'm satisfied with the half-yearresults, and although we're seeing increasing general uncertainty concerning theglobal economic situation and increased volatility in our end markets, we’reable to maintain our sales and earnings growth guidance for the full year,”says Steen Riisgaard, President & CEO. He continues:“With the expectation of a stable cash flow improvement over the next couple ofyears, Novozymes has decided to initiate a stock buyback program and togradually increase the dividend payout ratio, both starting in 2012. Finally, tosupport liquidity and to make Novozymes’ stock more accessible to retailshareholders, it has been decided to make a 1:5 stock split, expected to beeffective as of December 1, 2011.”

Comment by europe10 on Oct 20, 2011 4:51am
Hi Skyhi,I fully share your frustration with FEB.However, to compare with Novozymes is not really that interesting.They have a market cap of over 8 bio USD, and are market leaders in enzymes. And have been for many years. I have no figures of their sales of enzymes in the FEB potential market place, but if they have any sales they are miniscule compared to the size of this company.Enzymes do work, ...more